Paul Newey is a Senior Lecturer at the University of Dundee and Honorary NHS Consultant in Endocrinology & Diabetes at Ninewells Hospital & Medical School. He trained in Edinburgh and Oxford, undertaking his DPhil in molecular genetics in the field of Multiple Endocrine Neoplasia (MEN). His main areas of interest are in understanding the molecular and genetic basis of endocrine disorders including pituitary and parathyroid tumours. He is a co-author of the international guidelines for the management of Multiple Endocrine Neoplasia type 1 (MEN1) and has considerable clinical experience in the management of neuroendocrine tumours (NETs).

Dr Newey’s research primarily aims to understand the genetic basis of endocrine diseases. In particular, he is interested in identifying families with inherited endocrine disorders in an attempt to establish their genetic origin. He is also interested in understanding the contribution of rare genetic variants in disease predisposition by combining clinical and genetic information. Recently, Dr Newey has developed a programme of work examining disorders associated with aberrant prolactin signalling and aims to understand the role of the prolactin receptor in such conditions

Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med. 2013; 369; 2012-2020. Newey PJ, Nesbit MA, Rimmer AJ, Head RA, Gorvin CM, Attar M, Gregory L, Wass JA, Buck D, Karavitaki N, Grossman AB, McVean G, Ansorge O, Thakker RV. Whole-exome sequencing studies of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 2013; 98: E796-800. Newey PJ, Nesbit MA, Rimmer AJ, Attar M, Head RT, Christie PT, Gorvin CM, Stechman M, Gregory L, Mihai R, Sadler G, McVean G, Buck D, Thakker RV. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab. 2012; 97: E1995-2005. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML; Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97: 2990-3011. Newey PJ, Thakker RV. Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocr Pract. 2011;17 Suppl 3: 8-17 Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010; 31: 295-307. Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S, Johnson PR, Phillips RR, Ryan FJ, Shine B, Bowl MR, Thakker RV. Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2009; 94: 3640-6. Newey PJ, Bowl MR, Thakker RV. Parafibromin--functional insights. J Intern Med. 2009; 266: 84-98.